Second, the medicine everyone thought would take over the industry, Novo Nordisk's CagriSema, did not perform as well as expected in a phase 3 study. CagriSema could still be a commercial success ...

The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December.

The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo's targeted expectation of at least 25% weight loss. The press release ...

The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December. The experimental CagriSema shot ...

The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December. The experimental CagriSema shot missed ...

Earnings season is now well under way, with a number of major companies due to release results in the coming week. Investors will continue to keep a close eye on US president Donald Trump's trade ...

As the population of childhood cancer survivors continues to grow, however, evidence is increasing that cure from the primary malignancy is not without long-term complications. Virtually every ...

However, not all news has been positive. Novo Nordisk faced setbacks with its CagriSema obesity treatment, as the results from the REDEFINE-1 trial were disappointing, showing lower-than-expected ...

The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo's targeted expectation of at least 25% weight loss. The press release ...